A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).

Trial Profile

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Osimertinib (Primary) ; Savolitinib (Primary) ; Durvalumab; Selumetinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms TATTON
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Nov 2017 Planned number of patients changed from 298 to 308.
    • 03 Nov 2017 Planned End Date changed from 28 Dec 2018 to 28 Jun 2019.
    • 03 Nov 2017 Planned primary completion date changed from 28 Dec 2018 to 28 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top